| 7 | Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases显示文摘Dear Editor,Approximately 90%of men with metastatic castration-resistant prostate cancer(mCRPC)have bone metastases that can cause excruciating pain,bone fractures,disability,and death.13 Radium-223 is a radioactive isotope that mimics calcium and emits alpha particle radiation that selectively targets bone metastases.4,5 The results from the Alpharadin in Symptomatic Prostate Cancer Patients(ALSYMPCA)study,a phase 3 randomized controlled trial,showed that radium-223 improved overall survival(OS)and time to symptomatic skeletalrelated events(SRE)in men with mCRPC and bone metastases compared to placebo.6 Despite the FDA approval,radium-223 appears to be less utilized for the treatment of mCRPC compared to oral agents that target the androgen receptor pathway. | Anil Kapoor Nathan C Wong Yuding Wang Som Mukherjee Sebastien Hotte Ian Dayes Himu Lukka | 2020 | Asian Journal of Andrology2020，22，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员